Cargando…

Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma

Background: Transducin-like enhancer of split-1 (TLE1), a member of the Groucho/TLE family of transcriptional corepressors, has been reported to be involved in the tumorigenesis of various cancers and function as a clinical prognostic indicator. However, the mechanisms and prognostic significance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yizhi, Yuan, Da, Zhou, Li, Liang, Zhiyong, Zhou, Weixun, Lu, Jun, Jiang, Bolun, You, Lei, Guo, Junchao, Zhao, Yu-Pei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214815/ https://www.ncbi.nlm.nih.gov/pubmed/32432037 http://dx.doi.org/10.3389/fonc.2020.00576

Ejemplares similares

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
por: Jiang, Bolun, et al.
Publicado: (2020)

The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma
por: Ma, Qianli, et al.
Publicado: (2021)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma
por: Xu, Xinsen, et al.
Publicado: (2023)

Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section Histopathology
por: Ding, Guiling, et al.
Publicado: (2021)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Phosphomannose Isomerase High Expression Associated with Better Prognosis in Pancreatic Ductal Adenocarcinoma
por: Alipour, Zahra, et al.
Publicado: (2021)

Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma
por: Li, Haoran, et al.
Publicado: (2021)

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma
por: d’Engremont, Christelle, et al.
Publicado: (2021)

Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma
por: Huang, Xinyang, et al.
Publicado: (2022)

Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma
por: Fang, Lishan, et al.
Publicado: (2023)

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
por: Liu, Rong, et al.
Publicado: (2021)

Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation
por: Yu, Guiping, et al.
Publicado: (2022)

Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma
por: Liu, Hailiang, et al.
Publicado: (2020)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma
por: Gao, Yuzhen, et al.
Publicado: (2020)

Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma—A Research Based on the Evaluation of Whole-Mount Histological Slides
por: Li, Bo, et al.
Publicado: (2020)

Radiomics Model Based on MR Images to Discriminate Pancreatic Ductal Adenocarcinoma and Mass-Forming Chronic Pancreatitis Lesions
por: Deng, Yan, et al.
Publicado: (2021)

Corrigendum: Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma
por: Liu, Hailiang, et al.
Publicado: (2021)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation
por: Hu, Shanshan, et al.
Publicado: (2020)

Glutathione S-Transferase Mu-3 Predicts a Better Prognosis and Inhibits Malignant Behavior and Glycolysis in Pancreatic Cancer
por: Wang, Shunda, et al.
Publicado: (2020)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
por: Wu, Yang, et al.
Publicado: (2021)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer
por: Wang, Yizhi, et al.
Publicado: (2020)

Automatic Pancreatic Ductal Adenocarcinoma Detection in Whole Slide Images Using Deep Convolutional Neural Networks
por: Fu, Hao, et al.
Publicado: (2021)

A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019)

Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2019)

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021)

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2022)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4rseq5d0qfip16pg0tmuukgr5o